Yüklüyor......
The novel ATP-competitive MEK/Aurora kinase inhibitor BI-847325 overcomes acquired BRAF inhibitor resistance through suppression of Mcl-1 and MEK expression
Resistance to BRAF inhibitors is a major clinical problem. Here we evaluate BI-847325, an ATP-competitive inhibitor of MEK and Aurora kinases, in treatment-naïve and drug-resistant BRAF-mutant melanoma models. BI-847325 potently inhibited growth and survival of melanoma cell lines that were both BRA...
Kaydedildi:
| Yayımlandı: | Mol Cancer Ther |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4458462/ https://ncbi.nlm.nih.gov/pubmed/25873592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0832 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|